Core Viewpoint - 基石药业's stock price increased significantly, with a rise of 7.41% to HKD 7.39, driven by the announcement of clinical trial data and GIC's increased stake in the company [1] Group 1: Clinical Developments - 基石药业 presented preliminary data from the Phase I clinical trial of CS2009, a tri-specific antibody targeting PD1/VEGF/CTLA-4, at the 2025 ESMO conference [1] - The company also disclosed the design of the Phase Ib clinical trial for CS5001, an ADC targeting ROR1 [1] Group 2: Shareholder Activity - GIC disclosed on October 13 that it has increased its stake in 基石药业 to 6% [1] - This marks GIC's second significant purchase in less than two months, having previously acquired 80.4 million shares on August 18 for over HKD 630 million [1]

Core Viewpoint - 基石药业-B (02616) shares rose over 5% in early trading, reaching a peak increase of 7.41% at HKD 7.39, with a trading volume of HKD 54.65 million [1] Group 1: Clinical Research Developments - The company presented preliminary data from its Phase I clinical study of CS2009 (a PD1/VEGF/CTLA-4 trispecific antibody) at the 2025 ESMO conference [1] - Additionally, the design of the Phase Ib clinical study for CS5001 (a ROR1 antibody-drug conjugate) was disclosed [1] Group 2: Shareholder Activity - GIC disclosed on October 13 that it has increased its stake in 基石药业 to 6% [1] - This marks GIC's second significant purchase of the company's shares in less than two months, having previously acquired 80.4 million shares on August 18 for over HKD 630 million [1]

Core Insights - The company announced the presentation of preliminary data from its Phase I clinical study of CS2009 (a PD1/VEGF/CTLA-4 trispecific antibody) at the 2025 European Society for Medical Oncology (ESMO) annual meeting [1] - The company also revealed the design of its Phase Ib clinical study for CS5001 (a ROR1 antibody-drug conjugate) [1] Summary by Categories - **Clinical Research Updates** - Preliminary data for CS2009 was presented for the first time at a major oncology conference [1] - The design of the Phase Ib clinical study for CS5001 was disclosed [1]